SIM
MYGN icon

Sonora Investment Management’s Myriad Genetics MYGN Stock Holding History

Sonora Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$8K Hold
260
– – ﹤0.01% 816
2021
Q2 		$8K Buy
+260
New +$7.51K ﹤0.01% 742

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Sonora Investment Management's MYGN Position: Q3 2021 in Review

Sonora Investment Management held its Myriad Genetics (MYGN) position steady in Q3 2021 at 260 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #816.

Sonora Investment Management first reported a position in MYGN in Q2 2021 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold MYGN as of Q3 2021.

  • Sonora Investment Management held 260 shares of Myriad Genetics worth $8K as of Q3 2021.
  • Sonora Investment Management left its Myriad Genetics share count unchanged in Q3 2021.
  • Myriad Genetics made up ﹤0.01% of Sonora Investment Management's portfolio in Q3 2021, its #816 holding.
  • Sonora Investment Management first reported a position in Myriad Genetics in Q2 2021 and has held it in 2 quarters since.
  • 213 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2021.

Based on Sonora Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.